[Comment] Adjuvant aromatase inhibition: more options for patients

Aromatase inhibitors are the preferred treatment for postmenopausal patients with hormone receptor-positive early breast cancer.1 Third-generation aromatase inhibitors exist in two classes with different modes of action: reversible binding of the aromatase enzyme by the non-steroidal aromatase inhibitors anastrazole and letrozole, and irreversible inhibition of the enzyme by the steroidal aromatase inhibitor exemestane.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Comment Source Type: research